The Vast Uptake in Ruxolitinib for Vitiligo Treatment, Per John Harris of UMass Chain Medical School

John Harris, M.D., Ph.D., director of the Vitiligo Clinic and Research Center at UMass Chan Medical School, led a discussion today at the American Academy of Dermatology annual meeting in New Orleans. In this video interview, Harris talked about insurers adopting the FDA-approved vitiligo treatment, Ruxolitinib, any access barriers and the interest from patients. Harris also addressed body positivity when it comes to vitiligo, as patients want it to be accepted rather than seen as a condition.